Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Pharmacology and Experimental Therapeutics
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Journal of Pharmacology and Experimental Therapeutics

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Special Sections
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Submit
  • Visit jpet on Facebook
  • Follow jpet on Twitter
  • Follow jpet on LinkedIn
Research ArticleDrug Discovery and Translational Medicine

5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists

Jennifer L. Harmon, Lauren P. Wills, Caitlin E. McOmish, Elena Y. Demireva, Jay A. Gingrich, Craig C. Beeson and Rick G. Schnellmann
Journal of Pharmacology and Experimental Therapeutics April 2016, 357 (1) 1-9; DOI: https://doi.org/10.1124/jpet.115.228395
Jennifer L. Harmon
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Lauren P. Wills
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Caitlin E. McOmish
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Elena Y. Demireva
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jay A. Gingrich
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Craig C. Beeson
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Rick G. Schnellmann
Department of Drug Discovery and Biomedical Sciences, Medical University of South Carolina, Charleston, South Carolina (J.L.H., L.P.W., C.C.B., R.G.S.); Department of Psychiatry, Sackler Institute for Developmental Psychobiology, Columbia University, New York, New York (C.E.M., E.Y.D., J.A.G.); Division of Molecular Psychiatry, Florey Institute of Neuroscience and Mental Health, Melbourne Brain Centre, University of Melbourne, Parkville, Victoria, Australia (C.E.M.); Division of Developmental Neuroscience, New York State Psychiatric Institute, New York, New York (E.Y.D., J.A.G.); and Ralph H. Johnson Veterans Administration Medical Center, Charleston, South Carolina (R.G.S.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

In acute organ injuries, mitochondria are often dysfunctional, and recent research has revealed that recovery of mitochondrial and renal functions is accelerated by induction of mitochondrial biogenesis (MB). We previously reported that the nonselective 5-HT2 receptor agonist DOI [1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine] induced MB in renal proximal tubular cells (RPTCs). The goal of this study was to determine the role of 5-HT2 receptors in the regulation of mitochondrial genes and oxidative metabolism in the kidney. The 5-HT2C receptor agonist CP-809,101 [2-[(3-chlorophenyl)methoxy]-6-(1-piperazinyl)pyrazine] and antagonist SB-242,084 [6-chloro-2,3-dihydro-5-methyl-N-[6-[(2-methyl-3-pyridinyl)oxy]-3-pyridinyl]-1H-indole-1-carboxyamide dihydrochloride] were used to examine the induction of renal mitochondrial genes and oxidative metabolism in RPTCs and in mouse kidneys in the presence and absence of the 5-HT2C receptor. Unexpectedly, both CP-809,101 and SB-242,084 increased RPTC respiration and peroxisome proliferator–activated receptor γ coactivator-1α (PGC-1α) mRNA expression in RPTCs at 1–10 nM. In addition, CP-809,101 and SB-242,084 increased mRNA expression of PGC-1α and the mitochondrial proteins NADH dehydrogenase subunit 1 and NADH dehydrogenase (ubiquinone) β subcomplex 8 in mice. These compounds increased mitochondrial genes in RPTCs in which the 5-HT2C receptor was downregulated with small interfering RNA and in the renal cortex of mice lacking the 5-HT2C receptor. By contrast, the ability of these compounds to increase PGC-1α mRNA and respiration was blocked in RPTCs treated with 5-HT2A receptor small interfering RNA or the 5-HT2A receptor antagonist eplivanserin. In addition, the 5-HT2A receptor agonist NBOH-2C-CN [4-[2-[[(2-hydroxyphenyl)methyl]amino]ethyl]-2,5-dimethoxybenzonitrile] increased RPTC respiration at 1–100 nM. These results suggest that agonism of the 5-HT2A receptor induces MB and that the classic 5-HT2C receptor agonist CP-809,101 and antagonist SB-242,084 increase mitochondrial genes and oxidative metabolism through the 5-HT2A receptor. To our knowledge, this is the first report that links 5-HT2A receptor agonism to mitochondrial function.

Footnotes

    • Received August 3, 2015.
    • Accepted January 14, 2016.
  • This research was supported in part by the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grants F30DK091107 and T32DK083262 (to J.L.H.)]; the National Health and Medical Research Council [C.J. Martin Overseas Biomedical Fellowship (to C.E.M.)]; the Brain and Behavior Research Foundation [Young Investigator Award (to C.E.M.)]; the National Institutes of Health National Institute of Mental Health [Grants R21MH099458 and R01MH080116 (to J.A.G.)]; the National Institutes of Health National Institute of General Medical Sciences [Grants R01GM084147 (to R.G.S) and P20GM103542-02 (to South Carolina COBRE in Oxidants, Redox Balance, and Stress Signaling)]; the National Institutes of Health National Center for Research Resources [Grant UL1RR029882]; the Biomedical Laboratory Research and Development Program of the U.S. Department of Veterans Affairs [Grant 5I01 BX-000851 (to R.G.S.)]; and the South Carolina Clinical and Translational Research Institute at the Medical University of South Carolina. Animal facilities were funded by the National Institutes of Health National Center for Research Resources [Grant C06RR015455].

  • dx.doi.org/10.1124/jpet.115.228395.

  • U.S. Government work not protected by U.S. copyright
View Full Text

JPET articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Journal of Pharmacology and Experimental Therapeutics: 357 (1)
Journal of Pharmacology and Experimental Therapeutics
Vol. 357, Issue 1
1 Apr 2016
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Journal of Pharmacology and Experimental Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
5-HT2 Receptor Regulation of Mitochondrial Genes: Unexpected Pharmacological Effects of Agonists and Antagonists
(Your Name) has forwarded a page to you from Journal of Pharmacology and Experimental Therapeutics
(Your Name) thought you would be interested in this article in Journal of Pharmacology and Experimental Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleDrug Discovery and Translational Medicine

5-HT2 Receptor Regulation of Mitochondrial Genes

Jennifer L. Harmon, Lauren P. Wills, Caitlin E. McOmish, Elena Y. Demireva, Jay A. Gingrich, Craig C. Beeson and Rick G. Schnellmann
Journal of Pharmacology and Experimental Therapeutics April 1, 2016, 357 (1) 1-9; DOI: https://doi.org/10.1124/jpet.115.228395

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

Share
Research ArticleDrug Discovery and Translational Medicine

5-HT2 Receptor Regulation of Mitochondrial Genes

Jennifer L. Harmon, Lauren P. Wills, Caitlin E. McOmish, Elena Y. Demireva, Jay A. Gingrich, Craig C. Beeson and Rick G. Schnellmann
Journal of Pharmacology and Experimental Therapeutics April 1, 2016, 357 (1) 1-9; DOI: https://doi.org/10.1124/jpet.115.228395
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Authorship Contributions
    • Footnotes
    • Abbreviations
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Glucose transport modulators and mouse behavioral testing
  • Translational PK/PD Modeling of M3258
  • Kidney protective effects of BI 685509
Show more Drug Discovery and Translational Medicine

Similar Articles

Advertisement
  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About JPET
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Molecular Pharmacology
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0103 (Online)

Copyright © 2023 by the American Society for Pharmacology and Experimental Therapeutics